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Objective: Optimal preservation of postischemic graft function is essential in lung
transplantation. Antegrade flush perfusion with modified Euro-Collins solution
represents the standard technique worldwide. However, growing evidence suggests
the superiority of extracellular-type Perfadex solution (Vitrolife AB, Gothenburg,
Germany) over Euro-Collins solution. During ischemia and reperfusion, endoge-
nous pulmonary nitric oxide synthesis is decreased, and therefore therapeutic
stimulation of the nitric oxide pathway might be beneficial in ameliorating ischemia-
reperfusion damage. However, research mainly focuses on nitric oxide supplemen-
tation of intracellular solutions, and no studies exist in which the effect of nitro-
glycerin on Perfadex preservation quality is evaluated.
Methods: Eight rat lungs each were preserved with Perfadex solution with or
without nitroglycerin (0.1 mg/mL) and compared with low-potassium Euro-Collins
solution. Postischemic lungs were reventilated and reperfused, and oxygenation
capacity, pulmonary vascular resistance, and peak inspiratory pressures were mon-
itored continuously. Stereological analysis was used for evaluation of pulmonary
edema and assessment of the vasculature. Statistics were performed by using
different analysis of variance models.
Results: The oxygenation capacity of the Perfadex-preserved groups was higher
compared with that of the low-potassium Euro-Collins solution group (P .03). By
using nitroglycerin, flush-perfusion time was reduced, and Perfadex solution with
nitroglycerin–protected lungs showed superior oxygenation capacity compared with
that seen in Perfadex solution–protected organs (P  .01). Furthermore, pulmonary
vascular resistance and peak inspiratory pressures were improved in the nitroglyc-
erin group (P  .01). Stereology revealed comparable intrapulmonary edema
between groups and a trend toward less vasoconstricted vasculature in Perfadex with
nitroglycerin–protected lungs.
Conclusions: Perfadex solution provides superior lung preservation in terms of
postischemic oxygenation capacity than Euro-Collins solution. Supplementation of
the nitric oxide pathway by nitroglycerin further enhances functional outcome of
Perfadex-preserved organs and might be an easily applicable tool in clinical lung
transplantation.
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Lung transplantation is actually considered aneffective therapy in end-stage pulmonarydisease, but its application is limited by thesevere scarcity of suitable donor organs.Furthermore, the still-suboptimal preserva-tion techniques lead to various degrees of
ischemia-reperfusion injury.1 Therefore adequate preserva-
tion of the donor organ is an important issue to enhance the
applicability of the procedure with the aim to reduce organ
dysfunction, especially in the early postoperative period.
A number of different techniques for lung preservation
have been proposed in the last decade, but most institutions
still use single-flush perfusion with modified Euro-Collins
solution (EC) administered through the pulmonary artery.2
Alternative products, such as the low-potassium dextran
Perfadex solution (PER; Vitrolife AB, Go¨teborg, Sweden),
have been developed recently to improve the quality of
pulmonary allograft preservation. Those solutions of extra-
cellular electrolyte composition have been shown to signif-
icantly reduce the ischemia-reperfusion injury, with excel-
lent functional results in terms of postischemic
oxygenation.3-5 Because it has been shown that maintaining
vascular homeostasis in the pulmonary graft is one of the
most important determinants for successful lung preserva-
tion and transplantation,6 numerous experiments have fo-
cused on the addition of different protective agents to the
preservation solution. Endogenously produced nitric oxide
(NO) is released from endothelial cells and represents one
of the key factors for vascular homeostasis. As main effects,
NO causes smooth muscle relaxation with regulation of
pulmonary vascular tone, regulation of microvascular per-
meability, and inhibition of platelet aggregation.7 However,
it has been shown that endogenous NO synthesis is signif-
icantly decreased during lung ischemia and reperfusion.8
Therefore investigators evaluated the effect of application
of the NO donor nitroglycerin with subsequent stimulation
of the cyclic guanosine monophosphate pathway and re-
ported a significantly improved quality of lung preservation
when administered during the early preservation period.9-11
However, most of these reports still focused on lung pres-
ervation with EC, and there is little information thus far
concerning the effect of NO donors as an adjunct to the
modern extracellular-type preservation solutions. Therefore
the goal of this study was to analyze the effect of nitroglyc-
erin-enriched PER on the quality of lung preservation. In
addition to the evaluation of postischemic lung function,
lungs were further examined histologically by using stan-
dard stereological techniques that allow reliable and effi-
cient quantification of intrapulmonary edema.12,13
Material and Methods
Surgical Methods and Functional Assessment
Lungs of 24 anesthetized and mechanically ventilated male inbred
Sprague-Dawley rats (weight 450-500 g) were used for the exper-
iments. All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the Na-
tional Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, National Research Council, and
published by the National Academy Press, revised 1996. The
experiments were performed by using an established extracorpo-
real rat lung model, as described in detail previously.14
After laparotomy and thoracotomy, rats were assigned to one of
2 experimental groups: 8 lungs each were preserved with either
PER (Vitrolife Inc, Go¨teborg, Sweden) with (PER-NO) or without
nitroglycerin (Glyceroltrinitrat, 0.1 mg/mL; Schwarz Pharma,
Monheim, Germany). All results were compared with those of the
control lungs, which were preserved with modified low-potassium
EC (LPEC; 40 mval/L potassium) with prostacyclin (Flolan, 6 g/
100 mL; Glaxo Wellcome GmbH, Hamburg, Germany). Perfusion
was performed by using 20 mL of the corresponding preservation
solution at 4°C and a constant pressure of 20 cm H2O with
recording of the flush perfusion time. Throughout the entire per-
fusion period, the lungs were ventilated to allow for a homogenous
distribution of the perfusate. The heart-lung block was then care-
Figure 1. Extracorporeal lung circuit. The pulmonary artery is
perfused with blood from the lower reservoir (R2) by a small roller
pump (P1) at a defined rate of 8 mL/min with deoxygenated
xenogenic perfusate. Lungs are ventilated with room air under
physiologic time-pressure conditions provided by a small animal
respirator. The pulmonary venous blood drains into the main
reservoir (S1) and is recirculated by a second roller pump (P2) into
the upper reservoir (R1). Constant deoxygenation of perfusate is
maintained with specifically gassed standard oxygenators (D).
System temperature is controlled by use of water-jacketed ves-
sels and a thermostat. Different filter systems are included (F).
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fully excised, and the lungs were inflated with 10 cm3 of room air
and stored in the preservation solution at 10°C.
After storage, the lungs were reventilated and reperfused with
deoxygenated xenogenic perfusate containing bovine red blood
cells through a pulmonary arterial cannula. This extracorporeal
reperfusion circuit (Figure 1) consisted of a reservoir and a roller
pump (Multiflow bloodpump; Stoeckert Instruments Ltd, Munich,
Germany) to raise the perfusate to the reservoir. Also, a 40-m
blood filter (PALL Europe Ltd, Portsmouth, United Kingdom), a
membrane oxygenator (Monolyth integrated membrane lung;
Sorin Biomedica Ltd, Saluggia, Italy) that was gassed with 95%
N2 and 5% CO2, and a second roller pump (Reglo-Digital; Ismatec
Inc, Zurich, Switzerland) for continuous lung perfusion were in-
cluded. The perfusion rate was gradually increased from 1.0 to 8.0
mL/min during the first 9 minutes and was maintained at a constant
rate of 8.0 mL/min throughout the remaining reperfusion period.
All vessels were water-jacketed and temperature was controlled by
using a warming pump (water thermostat type Lauda M3B; Om-
nilab, Germany) at 37°C. Constant deoxygenation of the perfusate
to a PO2 of 10 to 15 mm Hg was achieved by means of regulation
of gas flow. The opening of the left atrial cannula was positioned
above the level of the atrium, ensuring a constant positive pressure
of 2 cm H2O (left atrial pressure).
Reperfusion time was limited to 50 minutes to specifically
assess the early postischemic period. Pulmonary artery pressures
and peak inspiratory pressures (PIPs) were measured continuously,
and pulmonary vascular resistance (PVR) was calculated. Blood
gases were determined in 10-minute intervals. For assessment of
the oxygenation ability of the reperfused lungs, the oxygenation
capacity was calculated (PaO2-PvO2). At the end of each experi-
ment, the entire left lung was excised, and the wet/dry (W/D) lung
weight ratio was determined by using the fresh weight of the lung
and the weight after storage for 48 hours in a cabinet dryer at 60°C.
Histologic Analysis
In all groups after the period of ischemia and reperfusion, the
entire right lung was processed for light microscopy after fixation
by means of vascular perfusion through the pulmonary artery with
a 1.5% paraformaldehyde-glutaraldehyde solution in 0.1 mol/L
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid buffer at a
pressure of 15 cm H2O. During fixation, the lungs were inflated,
with a constant pressure of 12 cm H2O. The tissue was dehydrated
through a graded series of ethanol and embedded in a methacrylate
resin (Technovit 7100; Kulzer, Heraeus, Germany). Systematic
random sampling of tissue was performed according to the method
of Michel and Cruz-Orive15 to collect lung material representative
of the whole lung. Slices of 3 mm in thickness were cut from each
lung (9-12 per lung) and stained with methyleneblue/Azur II (1:2).
All parameters were determined at the light microscopic level by
using established stereological techniques,12,13 with a Leitz Labor-
lux 11 and a Zeiss Axioskop equipped with a projection tube.
Statistical evaluation of W/D weight ratio, relative volume of
total lung edema, and vessel diameters was performed by using
analysis of variance with multiple comparisons. Oxygenation and
hemodynamic parameters during the reperfusion period were an-
alyzed by using analysis of variance with repeated measurements.
Results
Flush Perfusion Time
The perfusion time (Figure 2) was significantly lower in the
PER-NO group compared with that in the PER group (PER-
NO, 67  7 seconds; PER, 141  5 seconds, P  .001).
Perfusion time was longest but extremely variable in the
LPEC group (126 90 seconds), and this difference did not
reach statistical significance when compared with PER-
NO– or PER-protected lungs.
Oxygenation Capacity
After the ischemic period, all reperfused lungs resumed
sufficient function. Use of PER was associated with a trend
toward better oxygenation capacity (Figure 3), but the dif-
ference did not reach statistical significance because of the
high variability in the PER group (P  .079). However, the
oxygenation capacity of the PER-NO group was found to be
significantly higher compared with that of both LPEC lungs
(P  .001) and PER-protected organs (P  .001).
Figure 2. Flush perfusion time. Preservation groups were composed of LPEC, PER, and PER-NO: PER-NO versus
PER, P < .001.
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Pulmonary Vascular Resistance
In all study groups, PVR increased toward the end of the
reperfusion period (Figure 4). Although use of PER was
associated with similar PVR values when compared with
LPEC, lung preservation with PER-NO resulted in a signif-
icant reduction of PVR in comparison with values in both
the LPEC (P  .001) and PER (P  .001) groups.
Peak Inspiratory Pressure
After PER and PER-NO preservation, PIP was found to be
nearly unchanged over the reperfusion period (Figure 5). In
contrast, PIP values increased toward the end of the reper-
fusion period after LPEC preservation. Although use of
PER was associated with similar PIP values when compared
with user of LPEC, lung preservation with PER-NO re-
Figure 4. PVR of rat lungs during the observation period of 50 minutes. Preservation groups were composed of
LPEC, PER, and PER-NO: PER-NO versus PER, P < .001; PER-NO versus LPEC, P  .001.
Figure 5. PIP of rat lungs during the observation period of 50 minutes. Preservation groups were composed of LPEC,
PER, and PER-NO: PER-NO versus PER, P  .018.
Figure 3. Oxygenation capacity (PaO2-PvO2) of rat lungs during the observation period of 50 minutes. Preservation
groups were composed of LPEC, PER, and PER-NO: PER-NO versus PER, P  .001; PER-NO versus LPEC, P < .001.
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sulted in a significant reduction of PIPs compared with
values the PER group (P  .018).
W/D Ratio
Although there was a trend toward lower W/D ratios in
PER-protected (5.65  0.91) and PER-NO–protected (5.56
 1.06) organs compared with those seen in LPEC-pro-
tected organs (6.72  2.52), the noticed differences were
not significant (Figure 6).
Stereology
The relative volume fraction of edema (Figure 7) referred to
total lung volume was highest in LPEC-protected lungs
(16.85%  10.1%; Figure 8, B), whereas a significantly
lower amount of edema was observed after both PER
(1.22%  1.1%) and PER-NO (3.11%  3.27%) preserva-
tion (P  .003; Figure 8, A). The differences between both
PER-preserved groups were not statistically significant. Ste-
reological examination of relative volume fractions of ves-
sel lumen, vessel wall, and the calculated lumen/wall ratio
revealed results that did not reach statistical significance.
However, in contrast to the LPEC and PER groups, the
lumen/wall ratio of PER-NO–protected organs was found to
be almost identical to that seen in untreated control lungs
(Figure 9).
Discussion
Lung transplantation is considered to be an effective treat-
ment for many types of end-stage pulmonary disease. Com-
pared with initial results, the improved outcome is mainly
related to optimized immunosuppression regimens and
modified protocols for pulmonary preservation. However,
early graft dysfunction is still a continuing problem, result-
ing from a multifactorial lung injury starting within the
donor and continuing during harvesting, organ storage, im-
plantation, and postischemic reperfusion. Modified EC is
currently most widely used for lung preservation.2 How-
ever, it is well known that the high potassium concentration
of EC can cause severe pulmonary vasoconstriction, fol-
lowed by edema formation.16 This vasocontrictive effect
can lead to inhomogeneous perfusion caused by potassium-
induced vasospasm with a resulting prolongation of flush
preservation times.16 Accordingly, preservation time in our
series was longest when EC was used for lung preservation.
However, the high variability of flush preservation time in
our EC group is not well explained and has to be further
elucidated in future experiments.
Most centers still apply prostacyclin as an adjunct to the
EC to protect the lungs from inhomogeneous perfusion
caused by potassium-induced vasospasm.17 In recent years,
extracellular-type low-potassium solutions, such as PER,
have been developed for improvement of pulmonary pres-
ervation by minimizing vasospasm, consequently leading to
a more homogeneous distribution of the flush solution with
superior functional results.3-5 Because of the low potassium
content of PER, the need for additional application of pros-
taglandins has been resolved. Furthermore, there has been a
reasonable amount of evidence in the past that prostaglan-
dins are either of no use18,19 or even harmful.20 However, a
number of different techniques for improvement of lung
preservation have been proposed recently as a result of the
fact that the pulmonary vasculature seems to play a signif-
icant role in ischemia and reperfusion–induced lung injury.6
Among the numerous factors maintaining pulmonary vas-
cular homeostasis, NO is released from endothelial cells and
serves as an endothelium-derived relaxing factor that elicits
vasorelaxation mainly through activation of guanylate cy-
clase with a subsequent increase of cyclic guanosine mono-
phosphate levels.21 NO serves as an important signaling
molecule to reduce vasomotor tone of vascular smooth
muscles,11 to maintain endothelial barrier function,22 to
reduce platelet aggregation,23 and to inhibit neutrophil ad-
herence to the endothelial surface.24 After pulmonary isch-
Figure 6. W/D weight ratio of rat lungs after the observation period of 50 minutes. Preservation groups were
composed of LPEC, PER, and PER-NO. Differences were statistically not significant.
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emia in the setting of lung transplantation, these physiologic
endothelial properties are perturbed, which predisposes to
vasoconstriction, neutrophil adhesion, and thrombosis as the
ischemia-reperfusion response is activated. Systemic en-
dogenous NO levels are found to be significantly dimin-
ished after endothelial exposure to ischemia and reperfu-
sion, which is considered to be due to immediate
inactivation by the rapidly produced highly toxic superoxide
anion during early reperfusion.25 As a circulus vitiosus, the
lack of available NO is considered to contribute to endo-
thelial dysfunction and pulmonary graft failure during
reperfusion. Therefore several groups investigated the effect
of the NO donor nitroglycerin as an adjunct to the preser-
vation solution and reported significantly improved quality
of lung preservation.8,9,11 However, most of these reports
still focused on lung preservation with EC, and no studies
exist concerning the effect of nitroglycerin on PER-based
lung preservation.
Our experiments were thought to evaluate whether this
promising treatment is also suitable to further enhance the
published excellent preservation properties of the low-po-
tassium-dextran PER. Because the isolated rat lung seems to
be an ideal screening model for assessment of early postp-
reservation lung function, we used our established xeno-
genic, perfused small-animal model, as described previous-
ly.14 Obviously autologous blood would have been the
optimal perfusate for the experiments. However, in this rat
model only 6 mL/100 g of whole blood can be withdrawn
from a single rat. Therefore the amount of animals that
would have to be killed for one experiment contradicts the
advantage of a low-cost screening model. For this reason,
we used bovine red blood cells, as described by Lieberthal
and associates,26 which do not restrict the experiments to
the use of rodent red blood cells.27
In the past, there has been evidence that even after short
ischemic periods of 2 to 4 hours, primary ultrastructural
Figure 7. Volume fraction of intra-alveolar edema in rat lungs after the observation period of 50 minutes.
Preservation groups were composed of LPEC, PER, and PER-NO. Differences were statistically not significant.
Figure 8. Sections of lung parenchyma after preservation with PER (A; normal histologic structure without edema)
and modified EC (B; formation of intra-alveolar edema). AL, Alveolus; EN, endothelial cell; EP, epithelial cell; CA,
capillary; ED, edema.
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damage to the pulmonary surfactant system might occur. A
significantly increased permeability of the pulmonary endo-
thelium is considered to have important implications on the
initiation and extent of acute postischemic reperfusion ede-
ma.28 Therefore we decided to perform all experiments at
this rather short ischemic period of 4 hours to facilitate
future analyses of intrapulmonary surfactant and its degra-
dation products in early ischemia. Because it was reported
recently that the potential posttransplantation benefits of
exogenous nitroglycerin application are restricted to lungs
that were supplemented during the early harvest and im-
mersion period,10 the nitroglycerin in our series was added
to the preservation solution only. The dose of 0.1 mg/mL,
which was used for the experiments, is recommended in the
literature.8,9
In these experiments reperfusion time was limited to 50
minutes, which is considered to be sufficient to specifically
assess the early postischemic period.27 Obviously a longer
reperfusion period would deliver additional important infor-
mation because reperfusion injury clearly occurs over a
longer time period. Therefore the conclusions of this study
are limited by the rather short observation period used in the
experiments.
During reperfusion, the lowest oxygenation capacity was
found in LPEC-protected lungs, whereas the oxygenation
capacity of PER-NO–preserved organs was significantly
higher compared with that of both LPEC- and PER-pro-
tected organs (P  .03). However, a rather high variability
of oxygenation capacity was found in the PER group that is
not well explained and has to be further evaluated in addi-
tional experiments. Overall, the results obtained with nitro-
glycerin in PER confirm the available reports on the basis of
lung preservation with high-potassium solutions.8,11,29 Ad-
ditionally, the PVR was found to be significantly reduced
when PER-NO was used for preservation in contrast to
LPEC and PER, which was similarly reported by oth-
ers.10,29,30 Interestingly, the histologic analysis revealed a
trend toward a less constricted pulmonary vasculature,
which was expressed by a stereologically evaluated similar
high ratio of vessel lumen to vessel wall as that seen in
untreated normal control lungs. This finding might represent
the histologic correlate for the functional finding of lower
PVR in the PER-NO group. In contrast, the LPEC and PER
groups showed lower values, indicating a reduced relative
vessel lumen. However, the beneficial effects of nitroglyc-
erin supplementation are considered to be not exclusively
the result of its action as a vasodilator, because other potent
vasodilators, such as hydralazine, were found to be of no
comparable effect in terms of postischemic lung function.11
Recently, it was shown that endothelin 1 (ET-1) plays a
pivotal role in the control of pulmonary vascular tone.31,32
ET-1 is one of the most potent vasocontrictors known and is
synthesized and released by multiple cell types, especially
by vascular smooth muscle cells and endothelial cells.33
Accumulating evidence exists that endogenous NO inhibits
ET-1 production at the transcriptional level,34 and their
Figure 9. Ratio of stereologically determined volume fractions of vessel lumen to vessel wall. Preservation groups
were composed of LPEC, PER, and PER-NO. Differences were statistically not significant. Control, Untreated normal
control lungs.
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reciprocal balance largely determines the regulation of vas-
cular tone.35 Recent investigations found a striking increase
in the expression of ET-1 mRNA and ET-1 peptide after
lung transplantation and reperfusion. This process is con-
sidered to result in an increase of recipient PVR and in-
creased vascular permeability. In contrast, ET-1 mRNA was
significantly suppressed by the presence of exogenous ni-
troglycerin at the onset of preservation, even during ex-
tended periods of cold pulmonary preservation10 Interest-
ingly, in the same investigation the postischemic PVR was
found to be unchanged when nitroglycerin was administered
at the end of the flush preservation or during ex vivo
flushing. As an explanation, it appears that loss of endoge-
nous NO in the graft during preservation leads to upregu-
lation of ET-1 expression in the pulmonary vasculature and
subsequent irreversible vasoconstriction, which can not be
altered, even with the administration of exogenous nitro-
glycerin immediately before reperfusion. On the basis of
their positive findings after EC preservation, the authors
concluded that exogenous nitroglycerin given early during
the preservation period enhances posttransplantation pulmo-
nary function at least in part by modulation of ET-1 syn-
thesis. Although we did not perform measurements of ET-1
expression in our series, the observed results indicate that
supplementation of the PER with nitroglycerin can signifi-
cantly improve the postischemic functional results in terms
of oxygenation and PVR after moderate pulmonary isch-
emia. In contrast, lung preservation with modified EC is
associated with inferior oxygenation and hemodynamics in
combination with a significantly higher amount of intra-
alveolar edema. Because the relative volume fraction of
intra-alveolar edema was found to be comparable after
preservation with PER with and without the addition of
nitroglycerin, we hypothesize that the underlying mecha-
nism of action might at least in part be a significantly
suppressed induction of ET-1 in the graft during preserva-
tion and cold storage.
Additional experiments with this extracorporeal rat lung
model with extended ischemic and postischemic observa-
tion periods and an additional in vivo porcine model with
evaluation of ET-1 kinetics are being initiated to further
elucidate the promising results of nitroglycerin-supple-
mented PER. This approach could represent an easily ap-
plicable tool in clinical lung transplantation and has the
potential to further improve the excellent results of lung
preservation with PER, which has gained increased world-
wide acceptance in recent years.36,37
We gratefully acknowledge the expert technical assistance of S.
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Discussion
Dr Vaughn A. Starnes (Los Angeles, Calif). We know that
Euro-Collins solution can tend to be vasoconstrictive, and that is
the reason we started using prostacyclin way back when. Do you
have a group there in which you compared prostacyclin/Euro-
Collins with PER?
Dr Albes. Yes. In this particular model we added prostacyclin
to our Euro-Collins solution and compared it with both PER
groups.
Dr Thomas K. Waddell (Toronto, Ontario, Canada). I con-
gratulate you on your study. I think I generally believe the results,
but I would like to comment about some other potential control
groups that you might have included. Obviously nitroglycerin is a
vasodilator, and therefore you might consider, and I think you
suggested it yourself, that the flush time is shorter and, in fact, the
flush efficiency might be greater in the presence of a vasodilator.
Not to say that nitroglycerin is bad, but it might not be working
entirely through the NO pathway. Also, NO has other effects that
are mediated not through cyclic guanosine monophosphate
(cGMP). Therefore, you could try other ways of targeting both the
cGMP pathway and the non-cGMP pathway downstream of NO to
determine what exactly is responsible for the mechanism of ben-
efit.
Dr Albes. Thank you for this comment. It is certainly clear that
we can investigate much more. We intend to perform a large-
animal study to verify these initial findings, especially regarding
NO’s effects on the microvasculature.
Dr Irving L. Kron (Charlottesville, Va). I have one question.
NO has two faces, as you well know. Let us assume that it has the
effects you think it does. If you give it to a lung that is not having
any difficulty, it would work perfectly. But let us say injury has
already occurred, and many of us believe reperfusion injury is part
of the neurogenic pulmonary edema and that we just caught it at
the wrong time. Could it potentially have a deleterious effect in
that situation?
Dr Albes. NO surely has two faces because it is still a free
radical. Deleterious effects might therefore occur. However, those
were not observed by us. Unfortunately, it has always been a
problem in a small-animal experimental study to investigate many
details. We therefore had to remain concise and focus on just a few
aspects in our laboratory work.
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